The Structural Genomics Consortium, an Innovative Open-Access, Public–Private Partnership, Is a Viable Model for Drug Discovery
Mar 10, 2014
A knowledge platform for drug discovery
|PDF file||1.1 MB|
|PDF file||0.2 MB|
The Structural Genomics Consortium (SGC) supports drug discovery efforts through a unique, open access model of public-private collaboration. This report presents the results of an independent evaluation of the Structural Genomics Consortium, conducted by RAND Europe with the Institute on Governance. The evaluation aimed to establish the role of the SGC within the wider drug discovery and public-private partnership (PPP) landscape, assessing the merits of the SGC open access model relative to alternative models of funding R&D in this space, as well as the key trends and opportunities in the external environment that may impact on the future of the SGC. It also established the incentives and disincentives for investment, strengths and weaknesses of the SGC's model, and the opportunities and threats the SGC will face in the future. This enabled us to assess the most convincing arguments for funding the SGC at present; important trade-offs or limitations that should be addressed in moving towards the next funding phase; and whether funders are anticipating changes either to the SGC or the wider PPP landscape. Finally, we undertook a quantitative analysis to ascertain what judgements can be made about the SGC's past and current performance track record, before unpacking the role of the external environment and particular actors within the SGC in developing scenarios for the future.
The SGC in context: A review of relevant literature
The SGC as a model for investing in knowledge: Perspectives on the approach
The SGC as a model for generating knowledge: The model in practice
Extracting the value of knowledge: Outputs, outcomes and impacts of the SGC
Learning from the past to inform the future
What comes next for the knowledge platform?
Literature review material
SGC Researcher Survey Analysis
The research described in this report was prepared for and primarily funded by the Structural Genomics Consortium. It was also funded in part by the Policy Research Programme in the Department of Health. The research conducted by RAND Europe.
This report is part of the RAND Corporation Research report series. RAND reports present research findings and objective analysis that address the challenges facing the public and private sectors. All RAND reports undergo rigorous peer review to ensure high standards for research quality and objectivity.
This document and trademark(s) contained herein are protected by law. This representation of RAND intellectual property is provided for noncommercial use only. Unauthorized posting of this publication online is prohibited; linking directly to this product page is encouraged. Permission is required from RAND to reproduce, or reuse in another form, any of its research documents for commercial purposes. For information on reprint and reuse permissions, please visit www.rand.org/pubs/permissions.
The RAND Corporation is a nonprofit institution that helps improve policy and decisionmaking through research and analysis. RAND's publications do not necessarily reflect the opinions of its research clients and sponsors.